Y Jerold Gordon1, Eric G Romanowski, Alison M McDermott. 1. The Charles T. Campbell Ophthalmic Microbiology Laboratory, UPMC Eye Center, Department of Ophthalmology, University of Pittsburgh, Pittsburgh, Pennsylvania 15213, USA. gordonsj@upmc.edu
Abstract
PURPOSE: Antimicrobial peptides (AMPs) are an essential part of innate immunity that evolved in most living organisms over 2.6 billion years to combat microbial challenge. These small cationic peptides are multifunctional as effectors of innate immunity on skin and mucosal surfaces and have demonstrated direct antimicrobial activity against various bacteria, viruses, fungi, and parasites. This review summarizes their progress to date as commercial antimicrobial drugs for topical and systemic indications. METHODS: Literature review. RESULTS: Despite numerous clinical trials, no modified AMP has obtained Food & Drug Administration approval yet for any topical or systemic medical indications. CONCLUSIONS: While AMPs are recognized as essential components of natural host innate immunity against microbial challenge, their usefulness as a new class of antimicrobial drugs still remains to be proven.
PURPOSE: Antimicrobial peptides (AMPs) are an essential part of innate immunity that evolved in most living organisms over 2.6 billion years to combat microbial challenge. These small cationic peptides are multifunctional as effectors of innate immunity on skin and mucosal surfaces and have demonstrated direct antimicrobial activity against various bacteria, viruses, fungi, and parasites. This review summarizes their progress to date as commercial antimicrobial drugs for topical and systemic indications. METHODS: Literature review. RESULTS: Despite numerous clinical trials, no modified AMP has obtained Food & Drug Administration approval yet for any topical or systemic medical indications. CONCLUSIONS: While AMPs are recognized as essential components of natural host innate immunity against microbial challenge, their usefulness as a new class of antimicrobial drugs still remains to be proven.
Authors: Miguel E Quiñones-Mateu; Michael M Lederman; Zhimin Feng; Bikram Chakraborty; Jan Weber; Hector R Rangel; Michael L Marotta; Muneer Mirza; Bin Jiang; Patti Kiser; Kathy Medvik; Scott F Sieg; Aaron Weinberg Journal: AIDS Date: 2003-11-07 Impact factor: 4.177
Authors: Regis P Kowalski; Deepinder K Dhaliwal; Lisa M Karenchak; Eric G Romanowski; Francis S Mah; David C Ritterband; Y Jerold Gordon Journal: Am J Ophthalmol Date: 2003-09 Impact factor: 5.258
Authors: Andy Trotti; Adam Garden; Padraig Warde; Paul Symonds; Corey Langer; Rebecca Redman; Thomas F Pajak; Tomas R Fleming; Michael Henke; Jean Bourhis; David I Rosenthal; Elizabeth Junor; Anthony Cmelak; Finbarr Sheehan; Janis Pulliam; Patricia Devitt-Risse; Henry Fuchs; Mark Chambers; Brian O'Sullivan; K Kian Ang Journal: Int J Radiat Oncol Biol Phys Date: 2004-03-01 Impact factor: 7.038
Authors: M Moosazadeh Moghaddam; F Abolhassani; H Babavalian; R Mirnejad; K Azizi Barjini; J Amani Journal: Probiotics Antimicrob Proteins Date: 2012-06 Impact factor: 4.609
Authors: Michael S Gardner; Megan D Rowland; Amy Y Siu; Jonathan L Bundy; Diane K Wagener; James L Stephenson Journal: Anal Chem Date: 2009-01-15 Impact factor: 6.986